BottomBounce
1週前
50 Bullish Reasons to Be Super Bullish on $CGC
(Each bullet begins with a Guided Link, per your formatting rules.)
Global cannabis leadership — CGC remains one of the most recognized cannabis brands worldwide.
Canadian market scale — Canada is a federally legal market with long-term growth potential.
U.S. optionality — CGC has strategic exposure to the U.S. market through structure and partnerships.
Federal reform potential — Any U.S. reform (SAFE, rescheduling) could unlock massive upside.
Rescheduling momentum — U.S. rescheduling would lower taxes and boost profitability for the sector.
Brand portfolio strength — CGC owns multiple well-known cannabis and wellness brands.
Premium product positioning — Focus on higher-margin premium flower and extracts.
Medical cannabis expansion — Growing global demand for medical cannabis treatments.
International footprint — Presence in Canada, U.S., Germany, U.K., and other markets.
Germany legalization tailwind — Germany’s evolving cannabis laws could boost CGC’s European business.
European medical dominance — Europe is one of the fastest-growing medical cannabis markets.
Strong distribution channels — CGC products reach thousands of retail locations.
High-quality cultivation — Known for consistent, high-grade cultivation standards.
Cost-cutting progress — Major restructuring has reduced operating expenses.
Path to profitability — Leaner operations improve long-term margin potential.
Balance sheet improvement — Debt reduction and restructuring efforts underway.
Strategic partnerships — Collaborations with major companies across sectors.
Consumer packaged goods strategy — CGC aims to be a global CPG cannabis powerhouse.
Innovation pipeline — New product formats, beverages, edibles, and vapes.
Cannabis beverages — Infused beverages are a fast-growing category.
Health and wellness products — CBD and wellness lines expand non-THC revenue.
CBD market potential — Global CBD demand continues to rise.
Brand loyalty — Strong consumer loyalty in multiple product categories.
Retail expansion opportunities — Potential to expand retail presence in legal markets.
U.S. state-level growth — More U.S. states legalizing cannabis each year.
Cross-border synergies — Canada-U.S. integration could unlock efficiencies.
Global legalization trend — More countries moving toward legalization.
Institutional interest potential — U.S. reform could open the door to institutional capital.
Banking reform upside — SAFE Banking would reduce costs and improve access to capital.
Lower tax burden potential — Rescheduling could eliminate 280E taxes for U.S. operators.
Supply chain optimization — Streamlined operations improve margins.
Growing export markets — Export opportunities to Europe, Australia, and Latin America.
Pharmaceutical applications — Cannabis-based medicines are a long-term growth area.
IP and research assets — CGC has invested heavily in R&D and proprietary formulations.
Veterans medical programs — Growing acceptance of cannabis for PTSD and chronic pain.
Chronic pain market — Cannabis is increasingly used as an opioid alternative.
Mental health applications — Research into anxiety, sleep, and mood disorders.
Athlete partnerships — Sports leagues warming to cannabis and CBD.
Brand diversification — Multiple brands across price tiers and product types.
E-commerce opportunities — Online cannabis sales expanding in legal markets.
Vape category growth — Vapes remain one of the fastest-growing segments.
Edibles category growth — Edibles continue to gain market share.
Concentrates demand — High-potency products have strong consumer demand.
Tourism-driven sales — Cannabis tourism boosts sales in legal regions.
Sustainability initiatives — Eco-friendly cultivation appeals to ESG investors.
ESG investment potential — Cannabis aligns with wellness and sustainability themes.
Long-term demographic tailwinds — Younger generations overwhelmingly support legalization.
Shift from illicit to legal — Legal markets continue to capture illicit market share.
Massive total addressable market — Global cannabis TAM projected to reach tens of billions.
High-risk, high-reward upside — CGC is a leveraged play on global cannabis legalization. $MSOS
BottomBounce
2月前
$MSOS — What It Is
MSOS is the first U.S.-listed, actively managed ETF that provides pure exposure to U.S. cannabis companies, including multi-state operators that cannot list on U.S. exchanges due to federal illegality.
It achieves this exposure primarily through total-return swaps, which allow the ETF to track U.S. cannabis operators even though they trade on Canadian exchanges.
MSOS Portfolio Strategy
According to AdvisorShares:
It invests at least 80% of assets in U.S. cannabis companies or cannabis-related derivatives.
It is actively managed, adjusting positions as regulations and markets evolve.
It concentrates at least 25% of assets in the pharma/biotech/life-sciences cannabis group.
It is non-diversified, meaning it intentionally concentrates holdings for higher upside.
MSOS Portfolio Composition (Latest Data)
Top Holdings (as of latest reporting)
From Stock Analysis and TradingView data:
1. Derivatives Collateral (Nomura, NBC, Marex, CF Secured, Clearstreet)
These represent the cash collateral backing the swaps:
Nomura: 41.62%
NBC: 16.33%
Marex: 13.37%
CF Secured: 9.15%
Clearstreet: 3.90%
These are not cannabis companies — they are the financial institutions holding collateral for the swaps.
2. U.S. Cannabis Operators (via swaps + direct equity)
Curaleaf Holdings (CURA / swaps)
Swap exposure: 10.47%
Direct equity: 8.87%
Green Thumb Industries (GTI / swaps)
Swap exposure: 10.32%
Trulieve Cannabis
Swap exposure: 7.64%, 6.68%, 2.35%, etc.
TerrAscend (TSND)
Direct equity: 3.40%
Glass House Brands
Swap exposure: 3.66%
Verano Holdings
Swap exposure: 2.90%
Cresco Labs
Swap exposure: 2.54%
Jushi Holdings
Swap exposure: 0.86%
Village Farms (VFF)
Direct equity: 1.31%
SNDL
Direct equity: 0.42%
Sector Weighting
According to Yahoo Finance:
Real Estate: 50.19%
Industrials: 29.57%
Consumer Cyclical: 17.80%
These reflect how cannabis operators are classified (many own cultivation real estate, hence the heavy real-estate weighting).
Geographic Exposure
~72% U.S. exposure (largest cannabis market in the world)
How MSOS Gets U.S. Cannabis Exposure
Because U.S. cannabis is federally illegal, MSOS cannot directly hold many U.S. plant-touching companies in traditional equity form.
Instead, it uses:
Total-Return Swaps
These allow MSOS to mirror the performance of U.S. cannabis operators without holding the underlying shares directly.
This is why you see so many “swap” positions in the holdings list.
MSOS in One Sentence
MSOS is a high-conviction, actively managed ETF that gives investors exposure to the largest U.S. cannabis operators through swaps and equity, with heavy concentration in Curaleaf, Green Thumb, Trulieve, Verano, TerrAscend, Cresco, and Glass House.
BottomBounce
2月前
🌍 A Massive Global Industry
Recent market research shows the cannabis sector is already enormous and accelerating:
The global cannabis market was valued at USD 102.72 billion in 2025 and is projected to reach USD 1.43 trillion by 2034, growing at a 34.03% CAGR.
Another forecast projects the market rising from $57.18 billion in 2023 to $444.34 billion by 2030.
Additional analyses estimate growth from USD 39.21 billion in 2024 to USD 231.81 billion by 2035.
Across all major reports, the trend is consistent: cannabis is scaling into a trillion-dollar global industry.
💊 Why Demand Is Surging: A Global Shift Away From Big Pharma
Worldwide, consumers are increasingly turning to cannabis as an alternative to conventional pharmaceuticals. Several factors are driving this shift:
1. Rising interest in natural therapies
Consumers are seeking plant-based treatments for chronic pain, anxiety, sleep disorders, and inflammation—conditions traditionally treated with prescription drugs.
Market research highlights that cannabis is widely recognized for legitimate medicinal benefits, including pain relief and symptom management.
2. Declining reliance on opioids
Forecasts show that falling opioid prescriptions are directly linked to rising medical cannabis use, as patients and physicians look for safer, non-addictive options.
3. Pharmaceutical investment is rising
The pharmaceutical industry is projected to invest $5 billion by 2025 in cannabis-based drug development, targeting conditions such as PTSD, multiple sclerosis, and chronic pain.
4. FDA-approved cannabis-derived medicines
Products like Epidiolex®, Marinol®, and Syndros® are already approved for seizures and chemotherapy-related nausea, reinforcing cannabis as a legitimate medical treatment.
5. Global legalization momentum
Countries across North America, Europe, Asia, and Latin America are expanding medical cannabis programs, with Germany, Thailand, Canada, and the U.S. leading major policy shifts.
🧭 A Worldwide Demand Movement
Cannabis demand is rising across multiple sectors:
Medical cannabis now accounts for over 56.8% of market use.
CBD wellness products—oils, edibles, skincare, supplements—are surging as consumers seek non-psychoactive therapeutic options.
Recreational markets continue expanding as legalization spreads, with the U.S. projected to reach $428.22 billion by 2032.
This global shift reflects a broader cultural and medical trend: people want alternatives to traditional pharmaceuticals, and cannabis is filling that demand at scale.
📌 Bottom Line
The cannabis industry is now one of the largest and fastest-growing global markets, driven by:
Massive consumer demand for natural, plant-based medicine
Declining reliance on traditional pharmaceuticals
Expanding legalization
Strong medical evidence and pharmaceutical investment
With projections reaching trillion-dollar levels, cannabis has become a central pillar in the worldwide movement toward alternative health and wellness. $MSOS
BottomBounce
2月前
Medicare’s New CBD Pilot Opens the Door to THC—A Major Shift for Cannabis Policy
A new Medicare pilot program is set to reshape the medical-cannabis landscape in the United States. Federal health officials have confirmed that the initiative—designed to evaluate the therapeutic value and cost-effectiveness of CBD products—will allow limited amounts of THC in approved formulations. It’s a subtle change on paper, but a significant policy shift in practice.
For years, Medicare beneficiaries have been excluded from the medical-cannabis market entirely, even in states where cannabis is legal. The new pilot marks the first time the federal government will directly reimburse or evaluate cannabinoid-based treatments.
Why THC Matters in a CBD Pilot
CBD alone has shown benefits for anxiety, inflammation, and seizure disorders, but many clinicians argue that CBD works better with small, controlled amounts of THC. This is often referred to as the “entourage effect,” where cannabinoids enhance each other’s therapeutic impact.
By allowing THC within strict limits, Medicare is acknowledging what many researchers and patients have said for years: real-world cannabis medicine rarely fits into a CBD-only box.
The pilot will permit products containing trace to low THC levels, enough to support therapeutic synergy but not enough to produce intoxication.
Who Benefits
The move is especially significant for:
Chronic pain patients seeking alternatives to opioids
Seniors with arthritis, neuropathy, or sleep disorders
Patients in states with legal medical cannabis but limited financial access
Medicare beneficiaries represent one of the largest patient populations in the country, and many have been priced out of cannabis-based therapies.
Industry Impact
Cannabis companies producing compliant CBD-plus-THC formulations may see new opportunities. The pilot could:
Expand the market for federally reimbursable cannabinoid products
Encourage pharmaceutical-grade manufacturing standards
Push more research into low-THC therapeutic blends
Create a new regulatory pathway for cannabis-derived medicines
If the pilot succeeds, it could become a template for broader federal involvement in cannabinoid healthcare.
A Step Toward Federal Normalization
While the program does not legalize cannabis federally, it signals a shift in how federal agencies view cannabinoid medicine. Allowing THC—even in small amounts—within a Medicare framework would have been unthinkable a decade ago.
Today, it reflects a growing consensus: cannabis-based therapies are here to stay, and federal systems must adapt to them. $MSOS
BottomBounce
3月前
POTX – Global X Cannabis ETF
What it really focuses on
POTX is more index-like and concentrated in Canadian LPs and global cannabis producers:
Core holdings: Typically includes TLRY, Canopy, Cronos, Aurora, and other LPs as major weights, plus a handful of related global cannabis names.
Less ancillary, more producers: Compared with CNBS or YOLO, POTX tends to be more focused on producers and less on lenders, REITs, or pharma.
Why those stocks?
Index methodology: POTX tracks an index that screens for companies deriving a significant share of revenue from cannabis, which naturally pulls in LPs and major producers.
Leverage to wholesale pricing and capacity: LPs are highly sensitive to oversupply, pricing, and export markets—POTX is effectively a bet that this segment eventually rationalizes and recovers.
Market demand angle
Who buys POTX? Investors who want pure exposure to cannabis producers, especially Canadian LPs, in a rules-based ETF.
Demand drivers:
Speculative interest in a rebound of Canadian LPs after years of oversupply and write-downs.
Global medical and adult-use legalization that could open export markets for LPs.
How TLRY fits across all of them
In MJ and POTX: TLRY is a core, often top-tier holding—flows into these funds can significantly move TLRY.
In YOLO and CNBS: TLRY is an important but not dominant piece of a broader cannabis basket, sharing space with U.S. MSOs, other LPs, and ancillary names.
In MSOS: TLRY exposure, if any, is indirect and small; MSOS is really about U.S. MSOs, not TLRY. $POTX $MSOS $TLRY $CGC
BottomBounce
3月前
🍺 Alcohol Use in Wartime
Alcohol consumption historically rises during major conflicts, especially among soldiers and civilians under stress.
Why alcohol use increases
Stress, trauma, and uncertainty drive people toward coping behaviors.
Availability: Alcohol is usually legal and easier to obtain than illicit drugs.
Cultural norms: Drinking has long been embedded in military culture.
Evidence
Deployment is associated with unhealthy drinking and risky behaviors among service members.
Binge drinking rates in the military are higher than in the general population, even though other drug use is low.
🌿 Cannabis (Weed) Use in Wartime
Cannabis use does not reliably increase during wartime—at least not among active-duty troops.
Why cannabis use doesn’t rise in the military
Zero-tolerance policies
Mandatory drug testing
Severe penalties, including dishonorable discharge
Stigma around seeking help, which can discourage any behavior that risks detection
Evidence
Illicit drug use among active-duty personnel is under 1%, far lower than civilian rates.
Even though cannabis is widely used in civilian life, military enforcement keeps usage extremely low.
After service
Veterans sometimes show higher rates of substance use disorders, including cannabis, once they leave the military and lose those restrictive controls.
🧭 Civilian Populations During War
Outside the military, patterns vary:
Alcohol use tends to rise due to stress, scarcity, and social disruption.
Cannabis use depends on local laws, availability, and cultural norms.
In modern conflicts, where cannabis is legal in many regions, civilian use may increase—but this is context-dependent and not as well documented.
🧩 Bottom Line
Alcohol: Usually increases during wartime across both military and civilian populations.
Cannabis:
Active-duty military: Stays very low due to strict enforcement.
Civilians: Varies widely; may increase, but evidence is inconsistent. $MSOS $TLRY $WEED
BottomBounce
4月前
🌿 Global Cannabis Market
The worldwide cannabis and hemp sector was valued at about $38 billion in 2025.
It is expected to grow to around $49 billion in 2026, $61 billion in 2027, and could reach over $400 billion by 2035.
This reflects an exceptionally strong long-term growth rate of about 26% per year through 2035.
Growth is driven by expanding legalization, rising recreational use, and broader industrial hemp applications.
🏥 Medical Cannabis Market
The medical cannabis segment was worth about $30.6 billion in 2025.
It is projected to rise to $37.6 billion in 2026 and could reach nearly $196 billion by 2034.
This segment is growing at roughly 23% per year, fueled by increasing medical acceptance and use in treating chronic pain, epilepsy, cancer-related symptoms, and neurological conditions.
💧 CBD (Cannabidiol) Market
Multiple independent forecasts give a consistent picture:
The CBD market is valued at around $10–12 billion in 2025–2026.
Depending on the model, it is expected to reach $24–45 billion between 2031 and 2035.
Growth rates range from about 14% to 16% per year.
Demand is driven by wellness products, anxiety and sleep support, pain relief, and the dominance of hemp-derived CBD in North America.
🌱 Hemp Market
The search results do not provide a standalone global dollar value for hemp.
However, they confirm that hemp is the primary source for CBD production and is expected to expand rapidly as demand for CBD, industrial fibers, bioplastics, textiles, and construction materials increases.
Hemp’s growth trajectory closely follows the CBD market and the broader cannabis sector.
📈 Overall Demand Outlook (2026–2035)
Across all categories—cannabis, medical cannabis, CBD, and hemp—the global market is experiencing strong double-digit annual growth.
Key forces behind rising demand include:
Ongoing legalization in major regions
Medical adoption for chronic and severe conditions
Expansion of wellness and therapeutic CBD products
Industrial uses of hemp in manufacturing and sustainable materials
Innovation in cultivation, extraction, and product development $MSOS
SparklingMinotaur94
4月前
Cannabis already meets Schedule III standards.
The FDA approved Epidiolex, a cannabis based medicine, proving cannabinoids can be safe and effective. Large U.S. studies show cannabis helps chronic pain, nerve pain, and nausea from cancer treatment. Cannabis works with the body’s endocannabinoid system, which controls pain, inflammation, and brain signaling. Millions of patients use medical cannabis legally across most states, with studies linking access to fewer opioid deaths. Standardized oils allow precise dosing, similar to other prescription medicines.
The science and real world use are already there — Schedule III just needs recognition.
FDA Approved Medicine • Epidiolex (made from cannabis) was approved in 2018 for seizures. • This proves cannabis can be safe and helpful.
Links: FDA news: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf
2. Studies Show It Works • Big U.S. report (2017) says cannabis helps adults with long-term pain. Report: https://nap.nationalacademies.org/catalog/24625/the-health-effects-of-cannabis-and-cannabinoids-the-current-state-of-evidence-and-recommendations-for-research
• Another review (JAMA, 2015) says cannabis helps pain, nerve problems, and sickness from cancer medicine. JAMA: https://jamanetwork.com/journals/jama/fullarticle/2338251 PubMed: https://pubmed.ncbi.nlm.nih.gov/26103030/
3. How It Works Cannabis works with the body’s cannabinoid system: • Helps with pain • Helps with swelling • Helps the immune system • Helps the brain
Learn more: CB1 receptor: https://pubmed.ncbi.nlm.nih.gov/2825013/ Anandamide: https://pubmed.ncbi.nlm.nih.gov/1470919/
4. Real People Using Cannabis • 30+ states allow medical cannabis. Millions of people use it. • Study shows states with medical cannabis have fewer deaths from opioids. JAMA: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1898878 PubMed: https://pubmed.ncbi.nlm.nih.gov/25154332/
5. Easy-to-Take Oils • Cannabis can be put in oils like coconut oil to help the body use it better. • Drops give the same amount every time — safer than smoking. • Works like other plant-based medicines that become real medicines.
PK references: Oral absorption: https://pubmed.ncbi.nlm.nih.gov/31993665/ Oil delivery: https://pubmed.ncbi.nlm.nih.gov/23518184/
6. Bottom Line Cannabis already works for medicine:
FDA medicine exists
Studies show it helps
Body system explains how
Millions of patients see results
Oils make it easy to take
Schedule III is ready — regulators just need to say yes.
🌳 MRMD
SparklingMinotaur94
4月前
Cannabis is moving toward pharmaceutical cannabis, meaning formal research, pharmacy distribution, hospital use, and insurance coverage, which lowers cost and raises access by shifting it from weed shop to medicine.
If that shift happens, not all companies win; the early winners are the ones already built like medical operators, and MariMed fits that profile with established patient products, multi state operations, low debt, and a focus on medical demand instead of hype.
Odds favor rescheduling because the DEA, FDA, and lawmakers are already aligned in that direction, and if it happens, pharmaceutical cannabis companies like MariMed benefit first because they are already operating as if the rules have changed.
SparklingMinotaur94
4月前
Cannabis already meets Schedule III standards.
The FDA approved Epidiolex, a cannabis based medicine, proving cannabinoids can be safe and effective. Large U.S. studies show cannabis helps chronic pain, nerve pain, and nausea from cancer treatment. Cannabis works with the body’s endocannabinoid system, which controls pain, inflammation, and brain signaling. Millions of patients use medical cannabis legally across most states, with studies linking access to fewer opioid deaths. Standardized oils allow precise dosing, similar to other prescription medicines.
The science and real world use are already there — Schedule III just needs recognition.
FDA Approved Medicine • Epidiolex (made from cannabis) was approved in 2018 for seizures. • This proves cannabis can be safe and helpful.
Links: FDA news: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf
2. Studies Show It Works • Big U.S. report (2017) says cannabis helps adults with long-term pain. Report: https://nap.nationalacademies.org/catalog/24625/the-health-effects-of-cannabis-and-cannabinoids-the-current-state-of-evidence-and-recommendations-for-research
• Another review (JAMA, 2015) says cannabis helps pain, nerve problems, and sickness from cancer medicine. JAMA: https://jamanetwork.com/journals/jama/fullarticle/2338251 PubMed: https://pubmed.ncbi.nlm.nih.gov/26103030/
3. How It Works Cannabis works with the body’s cannabinoid system: • Helps with pain • Helps with swelling • Helps the immune system • Helps the brain
Learn more: CB1 receptor: https://pubmed.ncbi.nlm.nih.gov/2825013/ Anandamide: https://pubmed.ncbi.nlm.nih.gov/1470919/
4. Real People Using Cannabis • 30+ states allow medical cannabis. Millions of people use it. • Study shows states with medical cannabis have fewer deaths from opioids. JAMA: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1898878 PubMed: https://pubmed.ncbi.nlm.nih.gov/25154332/
5. Easy-to-Take Oils • Cannabis can be put in oils like coconut oil to help the body use it better. • Drops give the same amount every time — safer than smoking. • Works like other plant-based medicines that become real medicines.
PK references: Oral absorption: https://pubmed.ncbi.nlm.nih.gov/31993665/ Oil delivery: https://pubmed.ncbi.nlm.nih.gov/23518184/
6. Bottom Line Cannabis already works for medicine:
FDA medicine exists
Studies show it helps
Body system explains how
Millions of patients see results
Oils make it easy to take
Schedule III is ready — regulators just need to say yes.
🌳 MRMD
BottomBounce
4月前
$MSOS (AdvisorShares Pure U.S. Cannabis ETF)
Regulatory Catalyst
U.S. cannabis rescheduling reduces tax burdens and opens the door for broader institutional participation, directly benefiting ETF constituents.
Diversified Exposure
$MSOS provides access to multiple U.S. cannabis operators, spreading risk while capturing sector-wide upside.
Institutional Accessibility
As a liquid ETF, $MSOS offers funds and retail investors a regulated vehicle to gain cannabis exposure without single-stock risk.
Market Growth
U.S. cannabis sales continue to expand with new state legalizations, driving revenue growth across holdings.
Margin Expansion Potential
Scaled operators within $MSOS are positioned to improve profitability as tax burdens ease and economies of scale kick in.
M&A Consolidation
Constituents are actively pursuing acquisitions, creating stronger national players with pricing power.
Volatility Advantage
Cannabis stocks’ elevated volatility creates opportunities for options and algo-driven trading strategies tied to $MSOS.
Technical Setup
Chart signals show accumulation zones and breakout potential, aligning with algorithmic buy triggers.
Correlation Edge
Cannabis equities often trade independently of broader indices, offering diversification benefits for quant portfolios.
Policy Momentum
Federal banking reform and executive actions act as sentiment catalysts
BottomBounce
7月前
.
🌟 Optimistic Outlook for Tilray
1. Policy Shifts in Cannabis
A major driver would be changes in U.S. federal law. If cannabis is legalized or reclassified, Tilray could suddenly gain access to banking services, interstate trade, and a much larger consumer base.
Similar moves in Europe, especially Germany, could spark a domino effect across the EU, giving Tilray a strong foothold in international markets.
2. Strategic Growth Moves
Tilray has been diversifying into alcohol and craft beverages. If cannabis and alcohol distribution channels merge, it could create a powerful hybrid business model.
Expansion through acquisitions or partnerships in the U.S. would strengthen its presence and broaden revenue streams.
3. Financial Improvements
Investors would turn more positive if Tilray shows consistent profitability and trims down its debt load.
Demonstrating operational efficiency and sustainable margins would shift sentiment from speculative to growth-oriented.
4. Market Psychology
Tilray has a history of being a retail trader favorite. Any legalization headline could ignite a surge similar to past meme-stock rallies.
Renewed interest from institutional investors and ETFs could provide steady demand for shares.
📈 Potential Price Trajectories
Moderate upside: $90–$100 (post-split) if profitability aligns with regulatory progress.
Strong upside: $120–$150 (post-split) if U.S. legalization arrives quickly and Tilray capitalizes on it.
Aggressive upside: $200+ (post-split) only if legalization coincides with Tilray becoming a dominant global player across cannabis and alcohol.
⚡ Big Picture
Tilray’s bullish path is tied almost entirely to legal and regulatory breakthroughs. Without them, fundamentals alone won’t justify a triple-digit run. But if legalization momentum builds, Tilray’s scale and international reach could make it one of the biggest beneficiaries. $MSOS $TLRY
tw0122
7月前
"the “next era” of cannabis policy reform will deliver:
Banking protections, such as the SAFER Banking Act, which are still needed even if rescheduling happens.
Access to institutional capital and major market exchanges that could ease many operators’ debt crunches.
An end to advertising restrictions and punitive policies at third-party platforms like Meta’s Instagram, where cannabis accounts are routinely restricted or banned.
Research and development opportunities that could see cannabis firms discover proprietary medical formulations.
And, of course, 280E tax relief.
Moving cannabis to Schedule 3 of the Controlled Substances Act – as former President Joe Biden’s administration proposed, and as Trump promised to consider over the summer – would only tick the final bullet point off the list.
That means cannabis operators big and small must continue presenting their case to members of Congress.
And in in the meantime, they still need to make moves.
What savvy cannabis operators can do in the meantime
Savvy operators know too well the risk of basing a business plan on external forces over which they exert no control, such as federal reform."
https://mjbizdaily.com/how-cannabis-operators-are-preparing-for-federal-marijuana-reform/#:~:text=the%20%E2%80%9Cnext%20era,as%20federal%20reform
BottomBounce
7月前
Pure-Play U.S. Cannabis Exposure MSOS is the first actively managed U.S.-listed ETF dedicated solely to American cannabis companies, giving investors direct exposure to the sector.
Diversification Across Operators Instead of betting on one stock, MSOS spreads risk across multiple multi-state operators (MSOs) like Curaleaf, Green Thumb, Trulieve, and Cresco Labs.
Positioned for Legal Reform Any progress on U.S. cannabis reclassification, banking reform, or legalization could unlock massive growth for the ETF’s holdings.
Actively Managed Strategy Unlike passive ETFs, MSOS is actively managed, allowing portfolio adjustments to capture momentum and reduce downside risk.
Liquidity Access MSOS provides investors with a liquid way to invest in U.S. cannabis companies that otherwise trade on smaller exchanges or OTC markets.
Sector Growth Potential The U.S. cannabis market is projected to grow into tens of billions annually. MSOS is positioned to benefit from that expansion.
Political Catalysts Recent discussions around cannabis rescheduling and bipartisan support for SAFE Banking legislation have fueled optimism for MSOS.
Institutional Interest As regulations ease, institutional investors may enter the space, boosting valuations of MSOS holdings.
Consumer Demand Trends Cannabis consumption continues to rise across medical and recreational markets, providing a strong demand base for ETF constituents.
High Beta Opportunity MSOS tends to move sharply on policy news, offering traders and investors leverage to cannabis reform momentum.
📈 The Bullish Case Summarized
MSOS is essentially a bet on U.S. cannabis reform and growth. By pooling leading multi-state operators, it gives investors diversified exposure to a sector with explosive potential if legalization advances. For those bullish on cannabis policy change, $MSOS is one of the most direct vehicles to capture upside. $MSOS
BottomBounce
7月前
Why Trump might reclassify cannabis
There are several practical and political reasons why Trump could push for cannabis to be moved from its current strict federal category (Schedule I) to something less restrictive like Schedule III:
Medical legitimacy – It would officially recognize cannabis as having medical uses, which matches what many states already allow.
Criminal justice – Lower penalties would ease the burden on courts and prisons, especially for nonviolent drug offenses.
State alignment – With nearly half the states allowing recreational cannabis, federal law is badly out of sync.
Banking access – Cannabis businesses often can’t use banks because of federal rules. Reclassification would open the door to loans and safer financial practices.
Tax fairness – Right now, cannabis companies can’t deduct normal business expenses under IRS rules. Changing the classification would fix that.
Revenue growth – States have already collected tens of billions in cannabis taxes. Federal reform could add billions more in excise and income taxes.
Economic expansion – Legal cannabis supports jobs in farming, retail, and logistics. Reclassification would accelerate that growth.
Investor confidence – Cannabis stocks jump whenever reform looks likely, showing how markets expect big gains.
Voter appeal – Cannabis reform is popular across party lines, especially with younger and independent voters.
Campaign positioning – Trump has used cannabis reform as a way to show he’s pragmatic and willing to modernize outdated laws. $MSOS
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Wake Setter
2月前
DarthYoda
4月前
glenn1919
6月前
メールアドレスで登録
